This is the eighth drug using Dragonfly's
platform technology, and the sixth
TriNKET® to enter into clinical
trials.
WALTHAM,
Mass., March 5, 2024 /PRNewswire/ -- Dragonfly
Therapeutics, Inc., a clinical stage biotechnology company
developing novel immunotherapies, today announced receipt of a
milestone payment following dosing of the first patient in a
clinical trial conducted by AbbVie (NYSE: ABBV) to evaluate
ABBV-303, a solid tumor targeting TriNKET®.
ABBV-303, an investigational drug being developed for the
treatment of solid tumors, is the eighth drug using Dragonfly's
platform technology to enter the clinic, and the first
AbbVie-licensed TriNKET® drug candidate to
enter into the clinic. The Phase 1 clinical trial, conducted by
AbbVie, is evaluating ABBV-303 alone and in combination with
AbbVie's budigalimab (ABBV-181), in solid tumors.
"We are delighted that AbbVie has advanced ABBV-303 into
the clinic," said Bill Haney, CEO
and Dragonfly co-founder. "AbbVie is a global leader in advancing
novel treatments for some of the most complex diseases and a
terrific partner. We look forward to continued success and rapid
progress with the AbbVie team to advance potential new treatment
options for patients."
Additional information about the M24-122 Phase 1 trial, can be
found at: https://clinicaltrials.gov (ClinicalTrials.gov
Identifier: NCT06158958).
About Dragonfly
Dragonfly Therapeutics is a
clinical-stage biopharmaceutical company committed to discovering,
developing and commercializing novel therapies that harness the
body's immune system to bring breakthrough treatments to patients.
In addition to a set of advanced programs in the clinic, Dragonfly
has a deep pipeline of wholly owned preclinical candidates
discovered using its proprietary platforms that are progressing
toward the clinic, as well as productive collaborations with Merck,
AbbVie, Gilead and Bristol Myers
Squibb in a broad range of disease areas.
For more information visit:
www.dragonflytx.com
https://www.linkedin.com/company/dragonfly-therapeutics-inc./
https://twitter.com/dragonflytx
DRAGONFLY MEDIA CONTACT:
Anne E. Deconinck |
anne@dragonflytx.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/dragonfly-has-received-milestone-payment-following-dosing-of-first-patient-in-abbvie-phase-1-clinical-trial-evaluating-df4101abbv-303-302078923.html
SOURCE Dragonfly Therapeutics, Inc.